Asia-Pacific Sleep Apnea Devices Market Outlook, 2028

The increased prevalence of sleep apnea cases among the Asia-Pacific population is majorly driving the Asia-Pacific sleep apnea therapeutic device market. The Asia-Pacific sleep apnea device market is growing due to an ageing population and increased awareness about sleep apnea devices. By 2050, the Asia-Pacific area is expected to have one in every four people aged 60 and up. Because of physiological changes in their bodies, the elderly population is more prone to sleep apnea disorders. Elderly people suffering from obstructive sleep apnea frequently notice a decrease in their physical and cognitive capacities. They rely on sleep apnea equipment to improve their quality of life, fueling regional market growth. Advances in sleep apnea device technologies and innovations, a growing emphasis on the development of home-based sleep apnea devices for patient convenience, an increase in the number of research and development activities in the sleep apnea device industry, and supportive initiatives and campaigns by medical device organisations to raise sleep apnea awareness are driving market growth. Favourable reimbursement policies for sleep apnea devices in the region, an increasing number of collaborations and partnerships between manufacturers and healthcare providers, rising demand for effective and non-invasive sleep apnea treatment options, and rapid adoption of telemedicine and remote monitoring solutions for sleep apnea management all contribute to the market's rapid growth rate. Growing disposable income, increased healthcare costs in the Asia-Pacific region and an increase in the prevalence of sleep-related comorbidities associated with sleep apnea, such as obesity and cardiovascular disease, and government initiatives and policies promoting better sleep health and the management of sleep disorders further fuel the market. According to the research report "Asia-Pacific Sleep Apnea Therapeutic Devices Market Outlook, 2028," published by Bonafide Research, the Asia-Pacific Sleep Apnea Therapeutic Devices market is projected to add more than USD 785 Million from 2023 to 2028. Throughout the Asia-Pacific region, there is a growing awareness of sleep problems, especially sleep apnea. Changes in lifestyle, growing urbanisation, and rising obesity rates all contribute to the increased occurrence of sleep apnea. This increase in awareness is causing an increase in the number of people seeking diagnosis and treatment, which is driving the need for therapeutic devices. Rapid economic expansion in nations such as China, India, and Japan has led to greater healthcare spending and the construction of sophisticated healthcare infrastructure. This expansion improves access to sleep apnea diagnosis and treatment, boosting demand for therapeutic devices. Non-invasive treatment methods, such as sleep apnea therapy devices, are becoming more popular. Patients frequently prefer these devices to surgical treatments or medicines since they are non-invasive and effective at managing sleep apnea, leading to increased adoption. The market for sleep apnea therapeutic devices in Asia-Pacific is expanding rapidly, drawing both established global firms and smaller manufacturers. This competition promotes innovation, product diversification, and affordability, providing consumers with a broader range of options. Changes in lifestyle, such as increasing work-related stress, irregular sleep cycles, and sedentary habits, all contribute to the rising prevalence of sleep disorders. As a result, people are becoming more aware of the importance of sleep health, which is pushing the development of therapeutic devices to treat sleep apnea. Economic growth in several countries has led to increased affordability and accessibility of sleep apnea therapeutic devices. As disposable incomes rise, individuals have greater purchasing power, allowing more people to invest in these devices for better sleep health.

Based on country market is divided into five major countries, China, Japan, India, Australia and South Korea. Japan is playing crucial role in development of Asia-Pacific sleep apnea therapeutic devices market. Japan has a cutting-edge healthcare infrastructure with a significant emphasis on research and development. The country is home to renowned medical equipment makers and sleep medicine research facilities. This solid infrastructure promotes innovation and advances in sleep apnea therapy devices. Japan is well-known for its technological breakthroughs and innovation in a variety of fields, including healthcare. The country is constantly investing in the development of cutting-edge medical gadgets, such as sleep apnea therapy devices. Japanese firms are pioneers in device technology, improving comfort, use, and efficacy. Sleep disorders, particularly sleep apnea, are relatively common in Japan's population. This prevalence has generated greater interest in sleep medicine and the development of novel methods to address these problems, resulting in a focus on the advancement of therapeutic devices. Japan's government laws and legislation stimulate healthcare innovation. The government offers money and incentives for medical device research and development, establishing an atmosphere favourable to the advancement of sleep apnea therapy devices. Japan is a health-conscious society that places a premium on wellbeing and preventive healthcare. The general public's knowledge of the importance of sleep health leads to the need for effective sleep problem remedies, which stimulates the development of improved therapeutic equipment. In terms of product market is bifurcated into positive airway pressure (PAP) device, adaptive servo-ventilation (ASV), airway clearance systems, oxygen devices, oral appliances, and others. Adaptive servo-ventilation (ASV) product type is playing crucial role in development of sleep apnea therapeutic devices market. ASV devices provide a versatile therapy option that is especially useful for treating complex sleep-disordered breathing patterns such as central sleep apnea (CSA) and complex or mixed sleep apnea. ASV devices, unlike traditional Continuous Positive Airway Pressure (CPAP) machines, modify the airflow to the patient's breathing pattern, enabling personalised therapy. Central sleep apnea, which is frequently connected with heart failure, opiate use, or other underlying medical issues, can be difficult to treat. ASV devices are intended to address these complex breathing patterns by providing servo-controlled pressure support, thereby assisting in the normalisation of breathing and ventilation during sleep. ASV devices have demonstrated efficacy in treating treatment emergencies such as acute exacerbations of heart failure with sleep-disordered breathing. In critical situations, its capacity to quickly adapt and provide sufficient breathing assistance in response to changing respiratory needs is advantageous. ASV devices target a subset of the sleep apnea population that may not react well to standard CPAP or BiPAP therapy alone. The capacity of sleep apnea treatment devices to address complex breathing patterns broadens their market reach, providing an effective solution for a greater spectrum of patients. Based on end user segment market is bifurcated into home care settings & individuals and sleep laboratories and hospitals. Sleep laboratories and hospitals end users are growing at significant pace in Asia-Pacific sleep apnea market. In the Asia-Pacific region, there is an increasing awareness of sleep problems, especially sleep apnea. This increased awareness has resulted in an increase in the number of people seeking medical assistance and diagnosis for sleep-related illnesses. Sleep laboratories and hospitals with diagnostic equipment and expertise are critical to effectively identifying sleep disorders. Many Asia-Pacific countries are experiencing substantial growth in their healthcare infrastructure. This includes the construction of specialised sleep clinics, laboratories, and hospital-based sleep centres. The growth of healthcare facilities increases access to sleep diagnostic services, encouraging more people to seek examinations and treatment for sleep problems. The region's rising prevalence of sleep apnea adds to the expansion of sleep laboratories and hospitals as end users. As more people become aware of the illness, primary care physicians refer them to sleep experts and sleep laboratories for further evaluation, diagnosis, and treatment. Sleep apnea frequently necessitates specialised care and a thorough evaluation. Overnight sleep studies (polysomnography) and home sleep apnea testing (HSAT) are two services provided by sleep laboratories and hospitals that are critical for accurately evaluating the severity and type of sleep apnea.

Companies Covered in this report: ResMed Inc. , Fisher & Paykel Healthcare Corporation Limited, Koninklijke Philips N.V., GE HealthCare Technologies, Inc., BMC Medical Co Ltd, Invacare Corporation , Itamar Medical Ltd, Compumedics Ltd, Drive DeVilbiss Healthcare, Nihon Kohden Corporation, LivaNova, PLC. Considered in this report: • Geography: Asia-Pacific • Historic year: 2017 • Base year: 2022 • Estimated year: 2023 • Forecast year: 2028 Aspects covered in this report: • Asia-Pacific Sleep Apnea Therapeutic Devices market Outlook with its value and forecast along with its segments • Country-wise Sleep Apnea Therapeutic Devices market analysis • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation Country covered in the report: • China • Japan • India • Australia • South Korea By Product: • Positive Airway Pressure (PAP) Devices • Adaptive Servo-Ventilation (ASV) • Airway Clearance Systems • Oxygen Delivery Products • Oral Appliances • Others By End User: • Home care Settings & Individuals • Sleep laboratories & Hospitals The approach of the report: This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources. Intended audience: This report can be useful to industry consultants, manufacturers, suppliers, associations, and organisations related to the Sleep Apnea Therapeutic Devices industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.